Cargando…

Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF

AIMS: The PARAGLIDE-HF trial demonstrated reductions in natriuretic peptides with sacubitril/valsartan compared with valsartan in patients with heart failure (HF) with mildly reduced or preserved ejection fraction who had a recent worsening HF event, but was not adequately powered to examine clinica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vaduganathan, Muthiah, Mentz, Robert J, Claggett, Brian L, Miao, Zi Michael, Kulac, Ian J, Ward, Jonathan H, Hernandez, Adrian F, Morrow, David A, Starling, Randall C, Velazquez, Eric J, Williamson, Kristin M, Desai, Akshay S, Zieroth, Shelley, Lefkowitz, Martin, McMurray, John J V, Braunwald, Eugene, Solomon, Scott D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Fast Track Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424880/ https://www.ncbi.nlm.nih.gov/pubmed/37210743 http://dx.doi.org/10.1093/eurheartj/ehad344

Ejemplares similares

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
por: Wijkman, Magnus O., et al.
Publicado: (2022)

Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF
por: Peikert, Alexander, et al.
Publicado: (2022)

A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction
por: Vaduganathan, Muthiah, et al.
Publicado: (2020)

Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial
por: Morrow, David A, et al.
Publicado: (2019)

The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
por: Gronda, Edoardo, et al.
Publicado: (2020)

Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial
por: Bhatt, Ankeet S., et al.
Publicado: (2021)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
por: Lund, Lars H., et al.
Publicado: (2021)

Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER
por: Butt, Jawad H, et al.
Publicado: (2023)

Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trial
por: Vardeny, Orly, et al.
Publicado: (2019)

Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF
por: Curtain, James P., et al.
Publicado: (2022)

Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON‐HF
por: Mooney, Leanne, et al.
Publicado: (2021)

Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial
por: Metra, Marco, et al.
Publicado: (2022)

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
por: Docherty, Kieran F, et al.
Publicado: (2020)

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial
por: Vardeny, Orly, et al.
Publicado: (2016)

A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial
por: Mehra, Mandeep R, et al.
Publicado: (2019)

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
por: Curtain, James P, et al.
Publicado: (2021)

Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
por: Jhund, Pardeep S., et al.
Publicado: (2015)

Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM‐HF
por: Mogensen, Ulrik M., et al.
Publicado: (2017)

Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)
por: Mogensen, Ulrik M., et al.
Publicado: (2018)

Dapagliflozin for heart failure according to body mass index: the DELIVER trial( )
por: Adamson, Carly, et al.
Publicado: (2022)

Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP‐HF registry
por: Khariton, Yevgeniy, et al.
Publicado: (2020)

Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial( )
por: Tardif, Jean Claude, et al.
Publicado: (2022)

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial( )
por: Butler, Javed, et al.
Publicado: (2022)

Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
por: Chatur, Safia, et al.
Publicado: (2023)

Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction
por: Polito, Maria Vincenza, et al.
Publicado: (2020)

Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan
por: Hsu, Chien-Yi, et al.
Publicado: (2022)

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
por: Selvaraj, Senthil, et al.
Publicado: (2021)

ExaBayes: Massively Parallel Bayesian Tree Inference for the Whole-Genome Era
por: Aberer, Andre J., et al.
Publicado: (2014)

Complex Patterns of Admixture across the Indonesian Archipelago
por: Hudjashov, Georgi, et al.
Publicado: (2017)

At the Transition from Invertebrates to Vertebrates, a Novel GnRH-Like Peptide Emerges in Amphioxus
por: Roch, Graeme J., et al.
Publicado: (2014)

Genomic Divergence during Speciation Driven by Adaptation to Altitude
por: Chapman, Mark A., et al.
Publicado: (2013)

Recombination-Aware Phylogenomics Reveals the Structured Genomic Landscape of Hybridizing Cat Species
por: Li, Gang, et al.
Publicado: (2019)

A predictive model of the temperature-dependent inactivation of coronaviruses
por: Yap, Te Faye, et al.
Publicado: (2020)

Polyphenism of a Novel Trait Integrated Rapidly Evolving Genes into Ancestrally Plastic Networks
por: Casasa, Sofia, et al.
Publicado: (2020)

Good Codons, Bad Transcript: Large Reductions in Gene Expression and Fitness Arising from Synonymous Mutations in a Key Enzyme
por: Agashe, Deepa, et al.
Publicado: (2013)

Intra and Interspecific Variations of Gene Expression Levels in Yeast Are Largely Neutral: (Nei Lecture, SMBE 2016, Gold Coast)
por: Yang, Jian-Rong, et al.
Publicado: (2017)

Lateral Gene Transfer Shapes the Distribution of RuBisCO among Candidate Phyla Radiation Bacteria and DPANN Archaea
por: Jaffe, Alexander L, et al.
Publicado: (2019)

Genomic Adaptations to Salinity Resist Gene Flow in the Evolution of Floridian Watersnakes
por: Rautsaw, Rhett M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_esm4418vjr04nuqjjngivrabv3